Gilbert Halley E — SEC Form 4 filings
SEC reporting owner CIK 1601360. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-05-17 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 34,732 shares, $1,784,042 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 18,200 shares @ $73.00 ($1,328,600) in Vaxcyte, Inc., filed 2024-06-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | Director | 4 | — | 1 leg · 18,200 sh · $1,328,600 | 8 |
| Arcutis Biotherapeutics, Inc. (ARQT) | Director | 4 | — | 1 leg · 16,532 sh · $455,442 | 8 |
| CytomX Therapeutics, Inc. (CTMX) | Director | 3 | — | — | 3 |
Form 4 filings — Gilbert Halley E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 2,265 @ $0 · Grant/award (A): 11,389 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 12,220 @ $7.51 · Sale (S): 16,532 @ $27.55 · Option exercise (M): 12,220 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 3,041 @ $0 · Grant/award (A): 15,372 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 7,609 @ $0 · Grant/award (A): 20,568 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 10,139 @ $0 · Grant/award (A): 27,052 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 1,550 @ $0 · Grant/award (A): 7,250 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 18,200 @ $5.35 · Sale (S): 18,200 @ $73 · Option exercise (M): 18,200 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1601360 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →